Global Cat Vaccine Market Size, Share & Trends Analysis Report By Component, By Route of Administration (Injectables, Intranasal, and Oral), By Duration of Immunity, By Disease Type, By Type, By Regional Outlook and Forecast, 2024 - 2031
상품코드:1519543
리서치사:KBV Research
발행일:2024년 07월
페이지 정보:영문 302 Pages
라이선스 & 가격 (부가세 별도)
한글목차
고양이용 백신 시장 규모는 예측 기간 동안 9.2%의 복합 연간 성장률(CAGR)로 시장이 성장하여 2031년까지 25억 달러에 달할 것으로 예상됩니다.
게다가 고양이를 반려동물로 키우는 가구의 수가 증가함에 따라 고양이용 백신 수요가 크게 증가하고 있습니다. 이러한 경향은 도시화의 진전, 라이프스타일의 변화, 반려동물이 초래하는 정신적 및 교우 관계의 장점을 인식하는 등 다양한 요인의 영향을 받고 있습니다. 국제동물복지기금은 중국의에는 5,800만 마리의 고양이가 서식하고 있다고 추정하고 있으며, 아시아는 세계의 최대의 고양이 서식지가 되고 있습니다. 총 인구 6억명 중 4억마리가 고양이입니다. 따라서 고양이를 반려동물로 키우는 가구 수가 증가함에 따라 고양이용 백신 수요가 증가하고 있습니다.
그러나 지식 부족은 공공 장소에서 반려동물의 건강에 대한 관심이 일반적으로 부족하고, 건강 캠페인의 수가 불충분하고, 동시에 수의사 케어에 대한 액세스가 불충분한 등, 다양한 문제로 인해 발생할 수 있습니다. 많은 신흥 국가에서는 수의학 서비스가 도시 지역에 집중되어 있으며 농촌 지역 및 원격 지역 사회에서는 전문가의 조언과 서비스에 대한 액세스가 거의 없습니다. 따라서 고양이용 백신 접종의 중요성에 대한 인식과 교육의 부족은 고양이용 백신 시장의 성장에 큰 장애물이되었습니다.
게다가 유행의 초기 단계에서는 확실히 수의사 건강 관리 시스템에 부담이 걸렸습니다. 락다운과 소셜 디스턴스 대책에 의해 진료 시간의 단축이나 임시 휴업이 빈번하게 발생했습니다. 그 결과, 고양이의 정기 예방 접종과 같은 중요하지 않은 예약이 연기되거나 취소되었을 가능성이 높습니다. 게다가 COVID-19의 동물용 백신의 조사는 아직 초기 단계인 것, 장래에는 고양이용 COVID-19 백신에 특화된 시장이 태어날 가능성을 시사하고 있습니다. 따라서 유행은 시장에 전반적으로 중간 정도의 영향을 미쳤습니다.
유형의 전망
유형에 따라 시장은 약독생, 불 활성화(살균) 등으로 분류됩니다. 약독생 부문은 2023년 시장에서 48%의 수익 점유율을 획득했습니다. 약독생 부문은 더 적은 용량으로 강력하고 장기적인 면역력을 제공할 수 있기 때문에 고양이용 백신 시장을 선도하고 있습니다. 이 백신은 강력한 면역 반응을 자극하며 고양이 헤르페스 바이러스(FHV)와 고양이 칼리시 바이러스(FCV)에 매우 효과적입니다.
질병 유형의 전망
질병 유형에 따라 시장은 고양이 백혈병, 고양이 범백혈구 감소증(고양이 디스템퍼), 고양이 호흡기 질환, 고양이 광견병 등으로 분류됩니다. 고양이 백혈병 부문은 2023년 시장에서 10%의 수익 점유율을 기록했습니다. 고양이 백혈병 바이러스(FeLV)는 면역계에 미치는 영향과 암을 유발하는 능력으로 인해 고양이의 주요 사망 원인입니다. FeLV의 심각한 특성과 효과적인 백신을 사용할 수 있기 때문에 반려동물 주인은이 질병에 대한 예방 접종을 선호합니다.
투여 경로의 전망
투여 경로별로 보면, 시장은 주사, 비강, 경구로 나뉘어져 있습니다. 비강 부문은 2023년 시장에서 15%의 수익 점유율을 획득했습니다. 비강 백신은 고양이 바이러스성 비기관염과 칼리시바이러스와 같은 호흡기 질환에 특히 효과적입니다. 이 백신은 호흡기 시스템에 국소 면역 반응을 유도하는 이점이 있으며 비강으로 침입하는 병원체에 대한 강력한 방어를 제공합니다.
면역 기간의 전망
면역 기간에 따라 시장은 1년, 3년 등으로 분류됩니다. 1년 부문은 2023년 시장에서 49%의 수익 점유율을 획득했습니다. 이러한 백신은 보통 고양이 바이러스성 비기관염, 칼리시바이러스, 범백혈구감소증과 같은 핵심 백신 접종에 사용되며 효과적인 면역을 유지하기 위해 매년 추가 접종이 필요합니다. 투여 빈도에 따라 고양이는 일반적인 질병과 심각한 질병으로부터 계속 보호되므로 이러한 백신은 일상적인 수의사 관리의 클래식입니다.
성분 전망
성분에 따라 시장은 혼합 백신과 단맛 백신으로 나뉩니다. 혼합 백신 부문은 2023년 시장에서 62%의 수익 점유율을 기록했습니다. 단일 투여로 여러 질병으로부터 보호하는 이러한 백신은 편의성과 효율성을 높이 평가합니다. 혼합 백신은 필요한 주사 횟수를 줄임으로써 고양이에 대한 스트레스를 최소화하고 반려동물 주인과 수의사의 백신 접종 과정을 단순화합니다.
지역 전망
지역별로 보면 시장은 북미, 유럽, 아시아태평양의, 라틴아메리카의, 중동, 아프리카의에 걸쳐 분석되고 있습니다. 북미 부문은 2023년 시장에서 38%의 수익 점유율을 획득했습니다. 이 지역의 이점은 반려동물 사육률, 높은 수의학 건강 관리 인프라, 반려동물 건강 및 예방 접종에 대한 강한 의식에 의해 추진되고 있습니다. 특히 미국과 캐나다에는 정기적인 반려동물 백신 접종 일정을 촉진하는 강력한 규제 프레임워크와 공중 보건 캠페인이 있습니다.
목차
제1장 시장 범위와 조사 방법
시장의 정의
목적
시장 범위
세분화
조사 방법
제2장 시장 요람
주요 하이라이트
제3장 시장 개요
소개
개요
시장구성과 시나리오
시장에 영향을 미치는 주요 요인
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
시장의 과제
Porter's Five Forces 분석
제4장 고양이용 백신 시장에서 전개되는 전략
제5장 시장 : 성분별
세계의 혼합 백신 시장 : 지역별
세계의 단맛 백신 시장 : 지역별
제6장 시장 : 투여 경로별
세계의 주사 시장 : 지역별
세계의 경비시장 : 지역별
세계의 경구 시장 : 지역별
제7장 시장 : 면역기간별
세계의 1년 시장 : 지역별
세계의 3년 시장 : 지역별
세계의 기타 시장 : 지역별
제8장 시장 : 질환 유형별
세계의 고양이 호흡기 질환 시장 : 지역별
세계의 고양이 광견병 시장 : 지역별
세계의 고양이 백혈구 감소증(고양이 디스템퍼) 시장 : 지역별
세계의 고양이 백혈병 시장 : 지역별
세계의 기타 시장 : 지역별
제9장 시장 : 유형별
세계의 약독생 시장 : 지역별
세계의 불활화(살균) 시장 : 지역별
세계의 기타 시장 : 지역별
제10장 시장 : 지역별
북미
북미 시장 : 국가별
미국
캐나다
멕시코
기타 북미
유럽
유럽 시장 : 국가별
독일
영국
프랑스
러시아
스페인
이탈리아
기타 유럽
아시아태평양
아시아태평양 시장 : 국가별
중국
일본
인도
한국
싱가포르
말레이시아
기타 아시아태평양의
라틴아메리카, 중동, 아프리카의
라틴아메리카, 중동, 아프리카의 시장 : 국가별
브라질
아르헨티나
아랍에미리트(UAE)
사우디아라비아
남아프리카
나이지리아
기타 라틴아메리카의, 중동, 아프리카의
제11장 기업 프로파일
Zoetis, Inc
Elanco Animal Health, Inc
Merck & Co, Inc.
Boehringer Ingelheim International GmbH
Covetrus, Inc(Clayton, Dubilier & Rice, LLC)
Virbac
Heska Corporation(Antech Diagnostics, Inc)
Ceva Sante Animale
Bioveta, as
제12장 고양이용 백신 시장의 성공 필수 조건
BJH
영문 목차
영문목차
The Global Cat Vaccine Market size is expected to reach $2.5 billion by 2031, rising at a market growth of 9.2% CAGR during the forecast period.
The United Kingdom, Germany, and France have strict animal health regulations that require regular vaccinations, which contributes to the high compliance rates among pet owners. According to CATS REPORT 2022 published by Cats Protection, cat ownership levels vary across the UK, ranging from 24% of households in Scotland owning one or more cats to 28% of households in Wales. The growing trend of adopting stray and rescued cats, which require thorough vaccination schedules, further boosts the market in this region. Thus, the Europe region is expected to capture more than 1/4th revenue share in the market by the year 2031. A well-established veterinary care system and high levels of pet ownership support Europe's market. Additionally, the market demand is stimulated by the extensive awareness campaigns that European veterinary associations and government bodies conduct to educate pet owners about the significance of vaccinations.
The increasing prevalence of feline diseases has become a significant concern for pet owners, veterinarians, and public health officials. Among the most notable diseases are the feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), and rabies, all of which pose serious threats to the health and well-being of cats. This rise in disease incidence has heightened the urgency for effective vaccination programs to prevent potential outbreaks. Veterinarians also advocate for regular vaccination schedules to safeguard cats against these prevalent diseases. Therefore, the increasing prevalence of feline diseases has raised the demand for cat vaccines.
Additionally, the rising number of households adopting cats as pets has significantly increased the demand for cat vaccines. This tendency is affected by a number of different variables, including the growing urbanization, the shifting lifestyles, and the growing realization of the mental and companionship benefits that pets provide. The International Fund for Animal Welfare estimates that China is home to 58 million domestic cats, making Asia the home of the largest population of cats in the world, which accounts for 400 million out of a total population of 600 million. Hence, the increasing number of households adopting cats as pets has increased the demand for cat vaccines.
However, the lack of knowledge can be attributed to a variety of various problems, such as a general lack of concern for the health of pets in public discourse, an inadequate number of health campaigns, and an inadequate amount of access to veterinary care at the same time. In many developing countries, veterinary services are often concentrated in urban areas, leaving rural and remote communities with minimal access to professional advice and services. Hence, the lack of awareness and education about the importance of cat vaccinations is a significant obstacle to the growth of the cat vaccine market.
Moreover, the early stages of the pandemic undoubtedly caused a strain on the veterinary healthcare system. Lockdowns and social distancing measures often led to reduced clinic hours or temporary closures. This, in turn, likely resulted in a postponement or cancellation of non-essential appointments, including routine vaccinations for cats. Moreover, research into animal vaccines for COVID-19, while still in its early stages, suggests the potential for a future market dedicated specifically to cat COVID-19 vaccines. Thus, the pandemic had an overall moderate impact on the market.
Type Outlook
Based on type, the market is characterized into modified/attenuated live, inactivated (killed), and others. The modified/attenuated live segment garnered 48% revenue share in the market in 2023. The modified/attenuated live vaccine segment leads the cat vaccine market due to its ability to provide strong and long-lasting immunity with fewer doses. These vaccines stimulate a robust immune response, making them highly effective against feline herpesvirus (FHV) and feline calicivirus (FCV).
Disease Type Outlook
On the basis of disease type, the market is classified into feline leukemia, feline panleukopenia (feline distemper), feline respiratory diseases, feline rabies, and others. The feline leukemia segment recorded 10% revenue share in the market in 2023. Feline leukemia virus (FeLV) is a leading cause of death in domestic cats due to its impact on the immune system and its ability to cause cancer. The serious nature of FeLV and the availability of effective vaccines have driven pet owners to prioritize vaccination against this disease.
Route of Administration Outlook
By route of administration, the market is divided into injectables, intranasal, and oral. The intranasal segment garnered 15% revenue share in the market in 2023. Intranasal vaccines are particularly effective for respiratory diseases such as feline viral rhinotracheitis and calicivirus. These vaccines offer the advantage of inducing a local immune response in the respiratory tract, providing robust protection against pathogens that enter the nasal passages.
Duration of Immunity Outlook
Based on duration of immunity, the market is segmented into 1 year, 3 year, and others. The 1 year segment procured 49% revenue share in the market in 2023. These vaccines are typically used for core vaccinations such as feline viral rhinotracheitis, calicivirus, and panleukopenia, which require annual boosters to maintain effective immunity. The frequency of administration ensures that cats remain protected against common and potentially severe diseases, making these vaccines a staple in routine veterinary care.
Component Outlook
On the basis of component, the market is bifurcated into combined vaccines and mono vaccines. The combined vaccines segment recorded 62% revenue share in the market in 2023. These vaccines, which protect against multiple diseases in a single dose, are highly valued for their convenience and efficiency. By reducing the number of injections required, combined vaccines minimize the stress on cats and simplify the vaccination process for pet owners and veterinarians.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered 38% revenue share in the market in 2023. This region's dominance is driven by a high rate of pet ownership, advanced veterinary healthcare infrastructure, and strong awareness about pet health and vaccinations. In particular, the United States and Canada have robust regulatory frameworks and public health campaigns promoting regular pet vaccination schedules.
Recent Strategies Deployed in the Market
May-2024: Boehringer Ingelheim has announced the approval of SENVELGO(TM) (velagliflozin oral solution) by Health Canada for the treatment of feline diabetes. This milestone signifies a significant advancement in the management of diabetes mellitus in cats within Canada. SENVELGO(TM), a liquid oral solution, introduces a revolutionary approach that eliminates the necessity for needles, thereby simplifying the treatment process for cats previously untreated with insulin. This innovation aims to enhance glycemic control and improve the overall management of feline diabetes, offering a more convenient and accessible treatment option for pet owners and veterinarians alike.
Apr-2024: Zoetis launched Bonqat(R) (pregabalin oral solution) across veterinary clinics in the U.S. This introduction enhances Zoetis's range of products aimed at improving feline health, made available through an exclusive agreement with Orion Corporation. Bonqat represents a distinctive advancement in cat care, simplifying the process for pet owners to bring their cats to veterinary appointments. Additionally, it encourages more thorough care at clinics, encompassing diagnostics and preventative measures such as flea treatment, parasite control, and vaccination.
Apr-2024: Virbac acquired Sasaeah, a leading animal health player in Japan. We successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products for all the major species.
Sep-2022: Zoetis took over NewMetrica, develops health-related quality of life instruments, integrating health-related quality of life instruments into its companion animal portfolio. This strategic move aims to bolster capabilities throughout the care spectrum, deepen expertise in quality-of-life evaluations, and foster a deeper understanding of animal well-being. The addition of NewMetrica's tools and algorithms is anticipated to facilitate early disease detection and treatment, providing invaluable insights into the quality of life of pets. These advancements will play a crucial role in future product development efforts. The acquisition aligns closely with Zoetis's mission to enhance animal care, reflecting its commitment to promoting the well-being of animals and contributing positively to society and the environment.
Sep-2022: Zoetis Inc. revealed Solensia(TM) (frunevetmab injection) throughout the U.S. This marks a significant advancement in pet pain management, particularly for osteoarthritis (OA). Solensia(TM) offers a groundbreaking approach by providing relief from OA pain through a single monthly injection administered directly in the veterinary clinic. This innovation aims to minimize the impact of OA pain, preserving the special bond between cats and their human companions without disruption. Zoetis is committed to collaborating closely with veterinarians to introduce this novel monoclonal antibody treatment, enhancing the quality of life for cats and supporting their well-being through effective and convenient pain management solutions.
List of Key Companies Profiled
Zoetis, Inc.
Elanco Animal Health, Inc.
Merck & Co., Inc.
Boehringer Ingelheim International GmbH
Covetrus, Inc. (Clayton, Dubilier & Rice, LLC)
Virbac
Heska Corporation (Antech Diagnostics, Inc)
Ceva Sante Animale
Bioveta, a.s.
Global Cat Vaccine Market Report Segmentation
By Component
Combined Vaccines
Mono Vaccines
By Route of Administration
Injectables
Intranasal
Oral
By Duration of Immunity
1 Year
3 Year
Others
By Disease Type
Feline Respiratory Diseases
Feline Rabies
Feline Panleukopenia (Feline Distemper)
Feline Leukemia
Others
By Type
Modified/Attenuated Live
Inactivated (Killed)
Others
By Geography
North America
US
Canada
Mexico
Rest of North America
Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific
LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Cat Vaccine Market, by Component
1.4.2 Global Cat Vaccine Market, by Route of Administration
1.4.3 Global Cat Vaccine Market, by Duration of Immunity
1.4.4 Global Cat Vaccine Market, by Disease Type
1.4.5 Global Cat Vaccine Market, by Type
1.4.6 Global Cat Vaccine Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Cat Vaccine Market
Chapter 5. Global Cat Vaccine Market by Component
5.1 Global Combined Vaccines Market by Region
5.2 Global Mono Vaccines Market by Region
Chapter 6. Global Cat Vaccine Market by Route of Administration
6.1 Global Injectables Market by Region
6.2 Global Intranasal Market by Region
6.3 Global Oral Market by Region
Chapter 7. Global Cat Vaccine Market by Duration of Immunity
7.1 Global 1 Year Market by Region
7.2 Global 3 Year Market by Region
7.3 Global Others Market by Region
Chapter 8. Global Cat Vaccine Market by Disease Type
8.1 Global Feline Respiratory Diseases Market by Region
8.2 Global Feline Rabies Market by Region
8.3 Global Feline Panleukopenia (Feline Distemper) Market by Region
8.4 Global Feline Leukemia Market by Region
8.5 Global Others Market by Region
Chapter 9. Global Cat Vaccine Market by Type
9.1 Global Modified/Attenuated Live Market by Region
9.2 Global Inactivated (Killed) Market by Region
9.3 Global Others Market by Region
Chapter 10. Global Cat Vaccine Market by Region
10.1 North America Cat Vaccine Market
10.1.1 North America Cat Vaccine Market by Component
10.1.1.1 North America Combined Vaccines Market by Region
10.1.1.2 North America Mono Vaccines Market by Region
10.1.2 North America Cat Vaccine Market by Route of Administration
10.1.2.1 North America Injectables Market by Country
10.1.2.2 North America Intranasal Market by Country
10.1.2.3 North America Oral Market by Country
10.1.3 North America Cat Vaccine Market by Duration of Immunity
10.1.3.1 North America 1 Year Market by Country
10.1.3.2 North America 3 Year Market by Country
10.1.3.3 North America Others Market by Country
10.1.4 North America Cat Vaccine Market by Disease Type
10.1.4.1 North America Feline Respiratory Diseases Market by Country
10.1.4.2 North America Feline Rabies Market by Country
10.1.4.3 North America Feline Panleukopenia (Feline Distemper) Market by Country
10.1.4.4 North America Feline Leukemia Market by Country
10.1.4.5 North America Others Market by Country
10.1.5 North America Cat Vaccine Market by Type
10.1.5.1 North America Modified/Attenuated Live Market by Country
10.1.5.2 North America Inactivated (Killed) Market by Country
10.1.5.3 North America Others Market by Country
10.1.6 North America Cat Vaccine Market by Country
10.1.6.1 US Cat Vaccine Market
10.1.6.1.1 US Cat Vaccine Market by Component
10.1.6.1.2 US Cat Vaccine Market by Route of Administration
10.1.6.1.3 US Cat Vaccine Market by Duration of Immunity
10.1.6.1.4 US Cat Vaccine Market by Disease Type
10.1.6.1.5 US Cat Vaccine Market by Type
10.1.6.2 Canada Cat Vaccine Market
10.1.6.2.1 Canada Cat Vaccine Market by Component
10.1.6.2.2 Canada Cat Vaccine Market by Route of Administration
10.1.6.2.3 Canada Cat Vaccine Market by Duration of Immunity
10.1.6.2.4 Canada Cat Vaccine Market by Disease Type
10.1.6.2.5 Canada Cat Vaccine Market by Type
10.1.6.3 Mexico Cat Vaccine Market
10.1.6.3.1 Mexico Cat Vaccine Market by Component
10.1.6.3.2 Mexico Cat Vaccine Market by Route of Administration
10.1.6.3.3 Mexico Cat Vaccine Market by Duration of Immunity
10.1.6.3.4 Mexico Cat Vaccine Market by Disease Type
10.1.6.3.5 Mexico Cat Vaccine Market by Type
10.1.6.4 Rest of North America Cat Vaccine Market
10.1.6.4.1 Rest of North America Cat Vaccine Market by Component
10.1.6.4.2 Rest of North America Cat Vaccine Market by Route of Administration
10.1.6.4.3 Rest of North America Cat Vaccine Market by Duration of Immunity
10.1.6.4.4 Rest of North America Cat Vaccine Market by Disease Type
10.1.6.4.5 Rest of North America Cat Vaccine Market by Type
10.2 Europe Cat Vaccine Market
10.2.1 Europe Cat Vaccine Market by Component
10.2.1.1 Europe Combined Vaccines Market by Country
10.2.1.2 Europe Mono Vaccines Market by Country
10.2.2 Europe Cat Vaccine Market by Route of Administration
10.2.2.1 Europe Injectables Market by Country
10.2.2.2 Europe Intranasal Market by Country
10.2.2.3 Europe Oral Market by Country
10.2.3 Europe Cat Vaccine Market by Duration of Immunity
10.2.3.1 Europe 1 Year Market by Country
10.2.3.2 Europe 3 Year Market by Country
10.2.3.3 Europe Others Market by Country
10.2.4 Europe Cat Vaccine Market by Disease Type
10.2.4.1 Europe Feline Respiratory Diseases Market by Country
10.2.4.2 Europe Feline Rabies Market by Country
10.2.4.3 Europe Feline Panleukopenia (Feline Distemper) Market by Country
10.2.4.4 Europe Feline Leukemia Market by Country
10.2.4.5 Europe Others Market by Country
10.2.5 Europe Cat Vaccine Market by Type
10.2.5.1 Europe Modified/Attenuated Live Market by Country
10.2.5.2 Europe Inactivated (Killed) Market by Country
10.2.5.3 Europe Others Market by Country
10.2.6 Europe Cat Vaccine Market by Country
10.2.6.1 Germany Cat Vaccine Market
10.2.6.1.1 Germany Cat Vaccine Market by Component
10.2.6.1.2 Germany Cat Vaccine Market by Route of Administration
10.2.6.1.3 Germany Cat Vaccine Market by Duration of Immunity
10.2.6.1.4 Germany Cat Vaccine Market by Disease Type
10.2.6.1.5 Germany Cat Vaccine Market by Type
10.2.6.2 UK Cat Vaccine Market
10.2.6.2.1 UK Cat Vaccine Market by Component
10.2.6.2.2 UK Cat Vaccine Market by Route of Administration
10.2.6.2.3 UK Cat Vaccine Market by Duration of Immunity
10.2.6.2.4 UK Cat Vaccine Market by Disease Type
10.2.6.2.5 UK Cat Vaccine Market by Type
10.2.6.3 France Cat Vaccine Market
10.2.6.3.1 France Cat Vaccine Market by Component
10.2.6.3.2 France Cat Vaccine Market by Route of Administration
10.2.6.3.3 France Cat Vaccine Market by Duration of Immunity
10.2.6.3.4 France Cat Vaccine Market by Disease Type
10.2.6.3.5 France Cat Vaccine Market by Type
10.2.6.4 Russia Cat Vaccine Market
10.2.6.4.1 Russia Cat Vaccine Market by Component
10.2.6.4.2 Russia Cat Vaccine Market by Route of Administration
10.2.6.4.3 Russia Cat Vaccine Market by Duration of Immunity
10.2.6.4.4 Russia Cat Vaccine Market by Disease Type
10.2.6.4.5 Russia Cat Vaccine Market by Type
10.2.6.5 Spain Cat Vaccine Market
10.2.6.5.1 Spain Cat Vaccine Market by Component
10.2.6.5.2 Spain Cat Vaccine Market by Route of Administration
10.2.6.5.3 Spain Cat Vaccine Market by Duration of Immunity
10.2.6.5.4 Spain Cat Vaccine Market by Disease Type
10.2.6.5.5 Spain Cat Vaccine Market by Type
10.2.6.6 Italy Cat Vaccine Market
10.2.6.6.1 Italy Cat Vaccine Market by Component
10.2.6.6.2 Italy Cat Vaccine Market by Route of Administration
10.2.6.6.3 Italy Cat Vaccine Market by Duration of Immunity
10.2.6.6.4 Italy Cat Vaccine Market by Disease Type
10.2.6.6.5 Italy Cat Vaccine Market by Type
10.2.6.7 Rest of Europe Cat Vaccine Market
10.2.6.7.1 Rest of Europe Cat Vaccine Market by Component
10.2.6.7.2 Rest of Europe Cat Vaccine Market by Route of Administration
10.2.6.7.3 Rest of Europe Cat Vaccine Market by Duration of Immunity
10.2.6.7.4 Rest of Europe Cat Vaccine Market by Disease Type
10.2.6.7.5 Rest of Europe Cat Vaccine Market by Type
10.3 Asia Pacific Cat Vaccine Market
10.3.1 Asia Pacific Cat Vaccine Market by Component
10.3.1.1 Asia Pacific Combined Vaccines Market by Country
10.3.1.2 Asia Pacific Mono Vaccines Market by Country
10.3.2 Asia Pacific Cat Vaccine Market by Route of Administration
10.3.2.1 Asia Pacific Injectables Market by Country
10.3.2.2 Asia Pacific Intranasal Market by Country
10.3.2.3 Asia Pacific Oral Market by Country
10.3.3 Asia Pacific Cat Vaccine Market by Duration of Immunity
10.3.3.1 Asia Pacific 1 Year Market by Country
10.3.3.2 Asia Pacific 3 Year Market by Country
10.3.3.3 Asia Pacific Others Market by Country
10.3.4 Asia Pacific Cat Vaccine Market by Disease Type
10.3.4.1 Asia Pacific Feline Respiratory Diseases Market by Country
10.3.4.2 Asia Pacific Feline Rabies Market by Country
10.3.4.3 Asia Pacific Feline Panleukopenia (Feline Distemper) Market by Country
10.3.4.4 Asia Pacific Feline Leukemia Market by Country
10.3.4.5 Asia Pacific Others Market by Country
10.3.5 Asia Pacific Cat Vaccine Market by Type
10.3.5.1 Asia Pacific Modified/Attenuated Live Market by Country
10.3.5.2 Asia Pacific Inactivated (Killed) Market by Country
10.3.5.3 Asia Pacific Others Market by Country
10.3.6 Asia Pacific Cat Vaccine Market by Country
10.3.6.1 China Cat Vaccine Market
10.3.6.1.1 China Cat Vaccine Market by Component
10.3.6.1.2 China Cat Vaccine Market by Route of Administration
10.3.6.1.3 China Cat Vaccine Market by Duration of Immunity
10.3.6.1.4 China Cat Vaccine Market by Disease Type
10.3.6.1.5 China Cat Vaccine Market by Type
10.3.6.2 Japan Cat Vaccine Market
10.3.6.2.1 Japan Cat Vaccine Market by Component
10.3.6.2.2 Japan Cat Vaccine Market by Route of Administration
10.3.6.2.3 Japan Cat Vaccine Market by Duration of Immunity
10.3.6.2.4 Japan Cat Vaccine Market by Disease Type
10.3.6.2.5 Japan Cat Vaccine Market by Type
10.3.6.3 India Cat Vaccine Market
10.3.6.3.1 India Cat Vaccine Market by Component
10.3.6.3.2 India Cat Vaccine Market by Route of Administration
10.3.6.3.3 India Cat Vaccine Market by Duration of Immunity
10.3.6.3.4 India Cat Vaccine Market by Disease Type
10.3.6.3.5 India Cat Vaccine Market by Type
10.3.6.4 South Korea Cat Vaccine Market
10.3.6.4.1 South Korea Cat Vaccine Market by Component
10.3.6.4.2 South Korea Cat Vaccine Market by Route of Administration
10.3.6.4.3 South Korea Cat Vaccine Market by Duration of Immunity
10.3.6.4.4 South Korea Cat Vaccine Market by Disease Type
10.3.6.4.5 South Korea Cat Vaccine Market by Type
10.3.6.5 Singapore Cat Vaccine Market
10.3.6.5.1 Singapore Cat Vaccine Market by Component
10.3.6.5.2 Singapore Cat Vaccine Market by Route of Administration
10.3.6.5.3 Singapore Cat Vaccine Market by Duration of Immunity
10.3.6.5.4 Singapore Cat Vaccine Market by Disease Type
10.3.6.5.5 Singapore Cat Vaccine Market by Type
10.3.6.6 Malaysia Cat Vaccine Market
10.3.6.6.1 Malaysia Cat Vaccine Market by Component
10.3.6.6.2 Malaysia Cat Vaccine Market by Route of Administration
10.3.6.6.3 Malaysia Cat Vaccine Market by Duration of Immunity
10.3.6.6.4 Malaysia Cat Vaccine Market by Disease Type
10.3.6.6.5 Malaysia Cat Vaccine Market by Type
10.3.6.7 Rest of Asia Pacific Cat Vaccine Market
10.3.6.7.1 Rest of Asia Pacific Cat Vaccine Market by Component
10.3.6.7.2 Rest of Asia Pacific Cat Vaccine Market by Route of Administration
10.3.6.7.3 Rest of Asia Pacific Cat Vaccine Market by Duration of Immunity
10.3.6.7.4 Rest of Asia Pacific Cat Vaccine Market by Disease Type
10.3.6.7.5 Rest of Asia Pacific Cat Vaccine Market by Type
10.4 LAMEA Cat Vaccine Market
10.4.1 LAMEA Cat Vaccine Market by Component
10.4.1.1 LAMEA Combined Vaccines Market by Country
10.4.1.2 LAMEA Mono Vaccines Market by Country
10.4.2 LAMEA Cat Vaccine Market by Route of Administration
10.4.2.1 LAMEA Injectables Market by Country
10.4.2.2 LAMEA Intranasal Market by Country
10.4.2.3 LAMEA Oral Market by Country
10.4.3 LAMEA Cat Vaccine Market by Duration of Immunity
10.4.3.1 LAMEA 1 Year Market by Country
10.4.3.2 LAMEA 3 Year Market by Country
10.4.3.3 LAMEA Others Market by Country
10.4.4 LAMEA Cat Vaccine Market by Disease Type
10.4.4.1 LAMEA Feline Respiratory Diseases Market by Country
10.4.4.2 LAMEA Feline Rabies Market by Country
10.4.4.3 LAMEA Feline Panleukopenia (Feline Distemper) Market by Country
10.4.4.4 LAMEA Feline Leukemia Market by Country
10.4.4.5 LAMEA Others Market by Country
10.4.5 LAMEA Cat Vaccine Market by Type
10.4.5.1 LAMEA Modified/Attenuated Live Market by Country
10.4.5.2 LAMEA Inactivated (Killed) Market by Country
10.4.5.3 LAMEA Others Market by Country
10.4.6 LAMEA Cat Vaccine Market by Country
10.4.6.1 Brazil Cat Vaccine Market
10.4.6.1.1 Brazil Cat Vaccine Market by Component
10.4.6.1.2 Brazil Cat Vaccine Market by Route of Administration
10.4.6.1.3 Brazil Cat Vaccine Market by Duration of Immunity
10.4.6.1.4 Brazil Cat Vaccine Market by Disease Type
10.4.6.1.5 Brazil Cat Vaccine Market by Type
10.4.6.2 Argentina Cat Vaccine Market
10.4.6.2.1 Argentina Cat Vaccine Market by Component
10.4.6.2.2 Argentina Cat Vaccine Market by Route of Administration
10.4.6.2.3 Argentina Cat Vaccine Market by Duration of Immunity
10.4.6.2.4 Argentina Cat Vaccine Market by Disease Type
10.4.6.2.5 Argentina Cat Vaccine Market by Type
10.4.6.3 UAE Cat Vaccine Market
10.4.6.3.1 UAE Cat Vaccine Market by Component
10.4.6.3.2 UAE Cat Vaccine Market by Route of Administration
10.4.6.3.3 UAE Cat Vaccine Market by Duration of Immunity
10.4.6.3.4 UAE Cat Vaccine Market by Disease Type
10.4.6.3.5 UAE Cat Vaccine Market by Type
10.4.6.4 Saudi Arabia Cat Vaccine Market
10.4.6.4.1 Saudi Arabia Cat Vaccine Market by Component
10.4.6.4.2 Saudi Arabia Cat Vaccine Market by Route of Administration
10.4.6.4.3 Saudi Arabia Cat Vaccine Market by Duration of Immunity
10.4.6.4.4 Saudi Arabia Cat Vaccine Market by Disease Type
10.4.6.4.5 Saudi Arabia Cat Vaccine Market by Type
10.4.6.5 South Africa Cat Vaccine Market
10.4.6.5.1 South Africa Cat Vaccine Market by Component
10.4.6.5.2 South Africa Cat Vaccine Market by Route of Administration
10.4.6.5.3 South Africa Cat Vaccine Market by Duration of Immunity
10.4.6.5.4 South Africa Cat Vaccine Market by Disease Type
10.4.6.5.5 South Africa Cat Vaccine Market by Type
10.4.6.6 Nigeria Cat Vaccine Market
10.4.6.6.1 Nigeria Cat Vaccine Market by Component
10.4.6.6.2 Nigeria Cat Vaccine Market by Route of Administration
10.4.6.6.3 Nigeria Cat Vaccine Market by Duration of Immunity
10.4.6.6.4 Nigeria Cat Vaccine Market by Disease Type
10.4.6.6.5 Nigeria Cat Vaccine Market by Type
10.4.6.7 Rest of LAMEA Cat Vaccine Market
10.4.6.7.1 Rest of LAMEA Cat Vaccine Market by Component
10.4.6.7.2 Rest of LAMEA Cat Vaccine Market by Route of Administration
10.4.6.7.3 Rest of LAMEA Cat Vaccine Market by Duration of Immunity
10.4.6.7.4 Rest of LAMEA Cat Vaccine Market by Disease Type
10.4.6.7.5 Rest of LAMEA Cat Vaccine Market by Type
Chapter 11. Company Profiles
11.1 Zoetis, Inc.
11.1.1 Company Overview
11.1.2 Financial Analysis
11.1.3 Regional Analysis
11.1.4 Research & Development Expenses
11.1.5 Recent strategies and developments:
11.1.5.1 Partnerships, Collaborations, and Agreements:
11.1.5.2 Product Launches and Product Expansions:
11.1.5.3 Acquisition and Mergers:
11.1.6 SWOT Analysis
11.2 Elanco Animal Health, Inc.
11.2.1 Company Overview
11.2.2 Financial Analysis
11.2.3 Regional Analysis
11.2.4 Research & Development Expenses
11.2.5 SWOT Analysis
11.3 Merck & Co., Inc.
11.3.1 Company Overview
11.3.2 Financial Analysis
11.3.3 Segmental and Regional Analysis
11.3.4 Research & Development Expenses
11.3.5 SWOT Analysis
11.4 Boehringer Ingelheim International GmbH
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Regional & Segmental Analysis
11.4.4 Research & Development Expenses
11.4.5 Recent strategies and developments:
11.4.5.1 Trials and Approvals:
11.4.6 SWOT Analysis
11.5 Covetrus, Inc. (Clayton, Dubilier & Rice, LLC)
11.5.1 Company Overview
11.5.2 SWOT Analysis
11.6 Virbac
11.6.1 Company Overview
11.6.2 Financial Analysis
11.6.3 Regional Analysis
11.6.4 Recent strategies and developments:
11.6.4.1 Acquisition and Mergers:
11.6.5 SWOT Analysis
11.7 Heska Corporation (Antech Diagnostics, Inc)
11.7.1 Company Overview
11.7.2 SWOT Analysis
11.8 Ceva Sante Animale
11.8.1 Company Overview
11.8.2 SWOT Analysis
11.9 Bioveta, a.s.
11.9.1 Company Overview
Chapter 12. Winning Imperatives of Cat Vaccine Market